TNG961: A Selective HBS1L Molecular Glue Degrader for FOCAD-Deficient Cancer Research

TNG961 is an investigational oral molecular glue degrader designed to selectively degrade HBS1L in FOCAD-deficient cancer cells. By recruiting HBS1L to the CRBN-mediated protein degradation system, TNG961 disrupts the HBS1L/PELO ribosome rescue pathway and may expose a synthetic-lethal vulnerability in tumors with FOCAD loss. Preclinical research suggests potential relevance for cancers carrying 9p21-region deletions, including difficult-to-treat tumor types. Although still under investigation, TNG961 represents an important example of how targeted protein degradation may support precision oncology drug discovery.

Introduction: Why TNG961 Is Attracting Attention in Targeted Cancer Research

TNG961 is gaining attention in oncology drug discovery as a new example of a selective oral molecular glue degrader. Developed by Tango Therapeutics, TNG961 is designed to degrade HBS1L, a protein involved in the HBS1L/PELO ribosome rescue pathway. Unlike conventional small-molecule inhibitors that block protein activity, molecular glue degraders work by recruiting disease-relevant proteins to the cell’s protein degradation system, leading to their removal.

The scientific interest in TNG961 is closely linked to FOCAD-deleted cancers. FOCAD is located near the frequently deleted 9p21 chromosomal region, a genomic area often altered in several tumor types. When FOCAD is lost or disrupted, cancer cells may become more dependent on alternative survival pathways, creating a potential synthetic-lethal vulnerability. TNG961 is being investigated as a way to exploit this vulnerability by selectively degrading HBS1L in FOCAD-deficient tumor models.

This approach reflects a broader shift in precision oncology: instead of targeting cancer broadly, researchers are increasingly looking for genetic weaknesses that distinguish tumor cells from normal cells. By connecting FOCAD loss with HBS1L dependency, TNG961 may offer a new research direction for cancers with limited targeted treatment options. Although it remains investigational, TNG961 highlights the growing importance of molecular glue degraders in next-generation cancer therapy development.

Scientific Background: FOCAD Loss, HBS1L, and Synthetic Lethality

The scientific rationale behind TNG961 is based on the relationship between FOCAD loss, HBS1L function, and synthetic lethality. FOCAD is a tumor suppressor–associated gene located near the frequently deleted 9p21 chromosomal region. In some cancers, deletion or disruption of this region can remove FOCAD activity, creating a distinct biological state that may expose new therapeutic vulnerabilities.

One important vulnerability involves the HBS1L/PELO ribosome rescue pathway. HBS1L works together with PELO to help resolve stalled ribosomes during protein synthesis. This process supports normal translation quality control and helps cells maintain protein homeostasis. When FOCAD is absent, cancer cells may become more dependent on this ribosome rescue machinery to survive cellular stress and sustain abnormal growth.

This is where the concept of synthetic lethality becomes important. Synthetic lethality occurs when the loss of one gene or pathway is tolerated, but the simultaneous disruption of a second partner pathway becomes lethal to the cell. For FOCAD-deleted cancer cells, targeting HBS1L may create this type of selective pressure. By degrading HBS1L, TNG961 is designed to interfere with a survival mechanism that FOCAD-deficient cells rely on more heavily.

This biology makes TNG961 especially interesting for precision oncology research. Rather than attacking all dividing cells, it aims to exploit a specific genetic weakness found in selected tumor populations.

Mechanism of Action: How TNG961 Works as a Molecular Glue Degrader

TNG961 is designed to work through targeted protein degradation, a strategy that removes disease-relevant proteins rather than simply blocking their activity. Specifically, TNG961 functions as a molecular glue degrader that promotes the interaction between HBS1L and cereblon (CRBN), a substrate receptor of the CRL4 E3 ubiquitin ligase complex. By bringing HBS1L into proximity with this degradation machinery, TNG961 triggers HBS1L ubiquitination and subsequent proteasomal degradation.

This mechanism is different from traditional small-molecule inhibition. Instead of occupying an active site or blocking a signaling domain, TNG961 redirects the cell’s own protein disposal system to eliminate HBS1L from the cell. As HBS1L levels decrease, the HBS1L/PELO ribosome rescue pathway is disrupted. This can impair the ability of cancer cells to resolve stalled ribosomes, disturbing translation quality control and increasing cellular stress.

The selectivity of TNG961 is an important part of its design. Many CRBN-based molecular glues can affect multiple neo-substrates, which may raise safety or tolerability concerns. TNG961 has been described as a selective HBS1L degrader, meaning it is intended to degrade HBS1L while minimizing broader degradation of unrelated CRBN-associated proteins.

Through this mechanism, TNG961 connects molecular glue technology with synthetic-lethal cancer targeting. By selectively reducing HBS1L in FOCAD-deficient tumor cells, it may help expose a cancer-specific dependency that normal cells are less reliant on.

Preclinical Research Highlights and Potential Cancer Applications

Preclinical studies of TNG961 focus on its activity in FOCAD-deficient or FOCAD-deleted cancer models. These models are especially important because FOCAD loss may create a dependency on the HBS1L/PELO ribosome rescue pathway, making HBS1L degradation a potential synthetic-lethal strategy. By selectively reducing HBS1L levels, TNG961 is designed to interfere with a survival mechanism that certain genetically defined tumor cells may rely on.

Research findings suggest that TNG961 can inhibit the growth of FOCAD-negative cancer cells while showing a more selective effect compared with broader cytotoxic approaches. This selectivity is central to its potential value in precision oncology, where treatment strategies are increasingly guided by specific genomic alterations rather than tumor type alone.

TNG961 may be particularly relevant for cancers with deletions in the 9p21 chromosomal region, where FOCAD loss can occur. This region is frequently altered in several tumor types, including difficult-to-treat cancers such as pancreatic cancer. For tumors with limited targeted therapy options, identifying vulnerabilities linked to FOCAD deletion could open new research directions.

Although these preclinical results are promising, TNG961 remains an investigational compound. Further studies are needed to evaluate its safety, pharmacological profile, biomarker strategy, and potential clinical activity. Its current significance lies in demonstrating how molecular glue degraders may be used to target cancer-specific dependencies created by tumor suppressor loss.

Future Outlook: What TNG961 Could Mean for Molecular Glue Drug Discovery

TNG961 highlights the growing potential of molecular glue degraders in precision oncology. By selectively degrading HBS1L in FOCAD-deficient cancer cells, it shows how targeted protein degradation can be combined with synthetic-lethal strategies to address genetically defined tumor vulnerabilities. This approach may help expand the range of druggable targets beyond conventional enzymes, receptors, or signaling proteins.

One important future direction for TNG961 will be biomarker-driven development. Since its activity is closely linked to FOCAD loss, identifying patients or tumor models with FOCAD deletion, truncation, or functional deficiency will be essential. Reliable biomarker testing could help determine which cancers are most likely to respond to HBS1L degradation.

TNG961 also has broader implications for molecular glue discovery. Its selectivity for HBS1L suggests that molecular glues can potentially be designed with greater precision, reducing unwanted degradation of unrelated proteins. This is important for improving both efficacy and tolerability as the field moves toward clinical translation.